Clinical Trial Detail

NCT ID NCT02463032
Title Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors GTX
Indications

Her2-receptor negative breast cancer

Therapies

enobosarm

Age Groups: senior adult

Additional content available in CKB BOOST